# GHK-Cu Copper Peptide and Hair Growth Research

> GHK-Cu copper peptide and hair growth research shows 52–71 new hairs vs 9.6 placebo in a 6-month RCT, anagen induction in 6 days in mouse models, and a 2025 human alopecia study. Full evidence review.

## Does GHK-Cu Regrow Hair? What the Research Found

GHK-Cu copper peptide and hair growth research has produced some of the more clinically legible findings in the literature — a randomized controlled trial, a 2025 human retrospective study, and multiple mouse follicle models all pointing in the same direction.

**The landmark human trial:** Lee et al. (2016) randomized 45 males with androgenetic alopecia (Norwood-Hamilton II–V) to six months of topical treatment with a complex of 5-aminolevulinic acid and GHK peptide (ALAVAX) at 50 or 100 mg/mL, or placebo. Hair count at a 1-cm diameter area increased by 52.6 hairs in the 100 mg/mL group (p<0.05) and 71.5 hairs in the 50 mg/mL group (p<0.05), versus 9.6 in placebo. No adverse events [6].

**The 2025 human study:** Kuceki et al. (2025) assessed five monthly sessions of minoxidil-dutasteride-copper peptide delivered via tattoo-machine dermal infusion in 7 male AGA patients (Norwood-Hamilton III–IV). Median SALT score improved from 40.0% to 7.5%, median Top Scalp Area Regrowth (TSAR) was 26.5%, and 71.4% of patients exceeded the 10% regrowth threshold (p<0.001 vs baseline). No adverse reactions [17].

Both studies combine GHK or copper peptides with other active agents, which limits attribution of the effect specifically to GHK-Cu.

## GHK-Cu and Hair Follicle Stimulation: What the Studies Found

**Anagen phase extension.** In mouse topical studies using an ionic liquid microemulsion formulation (CaT-ME), hair follicles entered anagen within 6 days versus 8–9 days for minoxidil, and final hair density matched or exceeded minoxidil at 28 days [7]. The mechanism involves Wnt/beta-catenin activation and upregulation of VEGF and HGF.

**Dermal papilla cell proliferation and anti-apoptosis.** GHK-Cu promotes dermal papilla cell proliferation, inhibits their apoptosis, and stimulates their production of VEGF and HGF [21].

**TGF-beta suppression to prevent catagen.** GHK-Cu's suppression of TGF-beta1 signaling at the follicle level delays premature catagen entry — extending the effective growth window [21].

A 2025 review (Xu et al., 2025) summarizes GHK-Cu as "a powerful hair growth promoter with minimal side effects compared to minoxidil and finasteride," while identifying the transdermal bioavailability challenge as the primary bottleneck — approximately 95% of dermally injected GHK-Cu is metabolized before it can act [21].

## GHK-Cu in Hair Loss Research

The compound's proposed relevance in AGA is not through DHT blockade — GHK-Cu is not a 5-alpha-reductase inhibitor and does not suppress androgens [21]. Instead, the proposed mechanisms operate via reduced papilla vascularity, increased papilla apoptosis, and elevated catagen-triggering TGF-beta1 signaling — GHK-Cu addresses each of these independently.

## GHK-Cu and DHT: What the Hair Loss Research Shows

GHK-Cu is not a 5-alpha-reductase inhibitor. The compound does not suppress DHT synthesis and does not compete with androgens at the androgen receptor [21]. The 2025 dermal infusion study combined copper peptides with dutasteride (a DHT blocker) because the research community views these as complementary rather than overlapping mechanisms [17].

## GHK-Cu in Alopecia and Hair Thinning Research

The age-related drop in endogenous plasma GHK (from approximately 200 ng/mL at age 20 to under 80 ng/mL by age 60) may be relevant to age-associated hair thinning [3][11]. Keratinocyte growth factor (KGF) upregulation is the most directly hair-thinning-relevant mechanism in the preclinical record: KGF drives follicle proliferation and increases the diameter of miniaturized follicles [6][7].

## References

[3] Pickart L et al. BioMed Research International. 2015;2015:648108. https://pmc.ncbi.nlm.nih.gov/articles/PMC4508379/
[6] Lee WJ et al. Annals of Dermatology. 2016;28(4):438-443. https://pmc.ncbi.nlm.nih.gov/articles/PMC4969472/
[7] Liu T et al. Bioactive Materials. 2023. https://pmc.ncbi.nlm.nih.gov/articles/PMC10643103/
[11] He Q et al. Aging Pathobiology and Therapeutics. 2024;6(4):186-190. https://pmc.ncbi.nlm.nih.gov/articles/PMC12352503/
[17] Kuceki M et al. JAAD International. 2025. https://pmc.ncbi.nlm.nih.gov/articles/PMC11992372/
[21] Xu S et al. Pharmaceutics. 2025;17(8):984. https://pmc.ncbi.nlm.nih.gov/articles/PMC12389719/

---

Plain-language summaries of the peer-reviewed copper-peptide record — cited study by study, chapter by chapter, sold by no one.